On June 12, 2024, Lauren Riker, Senior Vice President, Finance at Pacira BioSciences Inc (PCRX, Financial), executed a sale of 3,970 shares of the company. The transaction was documented in an SEC Filing. Following this transaction, the insider now owns 38,075.335 shares of Pacira BioSciences Inc.
Pacira BioSciences Inc is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company primarily engages in the development of non-opioid products for the management of pain, with a leading product in the U.S. market.
Over the past year, Lauren Riker has sold a total of 3,970 shares and has not made any purchases of the company's stock. The insider transaction history for Pacira BioSciences Inc shows a total of 10 insider sells and no insider buys over the past year.
On the valuation front, shares of Pacira BioSciences Inc were trading at $28.72 on the day of the insider's recent transaction. This pricing gives the company a market cap of $1.321 billion. The price-earnings ratio stands at 19.57, which is below both the industry median of 22.945 and the company’s historical median.
According to the GF Value, which is an intrinsic value estimate from GuruFocus, Pacira BioSciences Inc has a GF Value of $46.65. With the current price of $28.72, the stock has a price-to-GF-Value ratio of 0.62, indicating that it is significantly undervalued.
The GF Value is calculated based on historical trading multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted by a GuruFocus factor which considers past returns and growth, and future business performance estimates provided by Morningstar analysts.
This recent insider sale might attract investor attention as they evaluate the stock's valuation metrics and consider the company's future prospects in the pharmaceutical industry.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
